Lupin gains on UKMHRA observation

Lupin Limited, which is a popular pharmaceutical company, announced about their successful completion of inspection undertaken by UK Medicines and Healthcare Products Regulatory Agency (UKMHRA).

UKMHRA is the regulatory agency of United Kingdom. Lupin stated that the inspection was undertaken at its three manufacturing units located in Pithampur (Madhya Pradesh, India) which concluded with no critical observation and one major observation. Satisfied with the conclusion, Nilesh Gupta, Managing Director of Lupin stated that the company is pleased with the outcome of the inspection as it is a meaningful development for the company’s Pithampur facility since Lupin is dedicated to maintain high quality standards at all its manufacturing units.

Lupin is an innovation-led transnational pharmaceutical company, developing and delivering a wide range of branded and generic formulations, biosimilar products, and APIs, globally. It is considered to be a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, Gl, Anti-Infective, NSAID areas and holds a global leadership position in the Anti-TB segment as well.

On Monday, the stock of Lupin closed at Rs 751.85, up by 1.59 per cent or Rs 11.75 per share. The intraday high was Rs 760.10 and intraday low was Rs 734.80. The 52-week high is Rs 887.70 and 52-week low is Rs 646.20 on BSE.